STOCK TITAN

LeMaitre (NASDAQ: LMAT) director gains PSU-based stock and dividend rights

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

LeMaitre Vascular director Lawrence J. Jasinski reported equity awards tied to performance share units. On February 26, 2026, he acquired 476 shares of common stock at no cost upon settlement of a PSU award granted on December 6, 2024, plus 1 additional common share from a derivative exercise.

The PSU award vested one‑third when the performance condition was determined satisfied on February 26, 2026, with the remaining two‑thirds vesting in equal annual installments over the next two years. Related dividend equivalent rights, economically equal to common stock, now total 2.8963 rights.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Jasinski Lawrence J

(Last) (First) (Middle)
C/O LEMAITRE VASCULAR, INC.
63 SECOND AVENUE

(Street)
BURLINGTON MA 01803

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/26/2026 A 476(1) A $0 5,798 D
Common Stock 02/26/2026 M 1(2) A $0(2) 5,799 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Dividend Equivalent Rights (3) 02/26/2026 M 1(3) (3) (3) Common Stock 1 $0 2.8963 D
Explanation of Responses:
1. These shares represent LMAT common stock acquired on February 26, 2026, upon settlement of a Performance Share Unit (PSU) award granted on December 6, 2024. The PSU award vested 1/3 upon determination of satisfaction of the performance condition (on 2/26/2026), and the balance vests in equal annual installments on the grant date anniversary over the next two years.
2. Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis.
3. These dividend equivalent rights were released in connection with the vesting of a PSU award granted on December 6, 2024. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
/s/ Laurie A. Churchill, Attorney-in-fact 03/02/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did LMAT director Lawrence Jasinski report on February 26, 2026?

Director Lawrence Jasinski reported acquiring equity awards on February 26, 2026. He received 476 shares of LeMaitre Vascular common stock at no cost from a performance share unit settlement, plus 1 additional share through a derivative exercise linked to dividend equivalent rights.

How many LMAT common shares does Lawrence Jasinski hold after this Form 4 filing?

After these transactions, Lawrence Jasinski directly holds 5,799 shares of LeMaitre Vascular common stock. This total reflects the 476-share PSU-related award and the 1 share acquired via derivative exercise, as disclosed in the non-derivative transaction table of the Form 4.

What are the key terms of Lawrence Jasinski’s LMAT performance share unit award?

The performance share unit award was granted on December 6, 2024. One-third vested on February 26, 2026, when the performance condition was determined satisfied, and the remaining two-thirds vest in equal annual installments on the grant date anniversary over the next two years.

How are dividend equivalent rights treated in Lawrence Jasinski’s LMAT equity awards?

Dividend equivalent rights are released in connection with the vesting of the PSU award. Each right is the economic equivalent of one share of LeMaitre Vascular common stock, and recent transactions increased his directly held dividend equivalent rights to a total of 2.8963 rights.

Did Lawrence Jasinski pay cash for the LMAT shares reported in this Form 4?

The reported transactions were recorded at a price per share of $0.00. Shares were acquired through settlement and vesting of a performance share unit award and associated derivative exercise, rather than through open-market purchases for cash consideration.
Lemaitre Vasculr

NASDAQ:LMAT

LMAT Rankings

LMAT Latest News

LMAT Latest SEC Filings

LMAT Stock Data

2.42B
20.71M
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
BURLINGTON